These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1343 related articles for article (PubMed ID: 16938720)

  • 1. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease.
    Van Assche G; Vanbeckevoort D; Bielen D; Coremans G; Aerden I; Noman M; D'Hoore A; Penninckx F; Marchal G; Cornillie F; Rutgeerts P
    Am J Gastroenterol; 2003 Feb; 98(2):332-9. PubMed ID: 12591051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
    Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report.
    van der Hagen SJ; Baeten CG; Soeters PB; Russel MG; Beets-Tan RG; van Gemert WG
    Dis Colon Rectum; 2005 Apr; 48(4):758-67. PubMed ID: 15750797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
    Tonelli F; Giudici F; Asteria CR
    Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.
    Ochsenkühn T; Göke B; Sackmann M
    Am J Gastroenterol; 2002 Aug; 97(8):2022-5. PubMed ID: 12190171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment with chimeric monoclonal antitumor necrosis factor (infliximab) of patients with active steroid-dependent/resistant Crohn's disease and fistulas].
    Martorana G; Casà A; Oliva L; Orlando A; Cottone M
    Recenti Prog Med; 2001; 92(7-8):451-5. PubMed ID: 11475786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
    Bouguen G; Trouilloud I; Siproudhis L; Oussalah A; Bigard MA; Bretagne JF; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local injection of Infliximab for the treatment of perianal Crohn's disease.
    Poggioli G; Laureti S; Pierangeli F; Rizzello F; Ugolini F; Gionchetti P; Campieri M
    Dis Colon Rectum; 2005 Apr; 48(4):768-74. PubMed ID: 15768185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab for the treatment of fistulas in patients with Crohn's disease.
    Present DH; Rutgeerts P; Targan S; Hanauer SB; Mayer L; van Hogezand RA; Podolsky DK; Sands BE; Braakman T; DeWoody KL; Schaible TF; van Deventer SJ
    N Engl J Med; 1999 May; 340(18):1398-405. PubMed ID: 10228190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
    Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
    Orlando A; Colombo E; Kohn A; Biancone L; Rizzello F; Viscido A; Sostegni R; Benazzato L; Castiglione F; Papi C; Meucci G; Riegler G; Mocciaro F; Cassinotti A; Cosintino R; Geremia A; Morselli C; Angelucci E; Lavagna A; Rispo A; Bossa F; Scimeca D; Cottone M;
    Dig Liver Dis; 2005 Aug; 37(8):577-83. PubMed ID: 15886081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn's disease: when and how were the seton drains removed?
    Tanaka S; Matsuo K; Sasaki T; Nakano M; Sakai K; Beppu R; Yamashita Y; Maeda K; Aoyagi K
    Hepatogastroenterology; 2010; 57(97):3-7. PubMed ID: 20422862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
    Gaertner WB; Decanini A; Mellgren A; Lowry AC; Goldberg SM; Madoff RD; Spencer MP
    Dis Colon Rectum; 2007 Nov; 50(11):1754-60. PubMed ID: 17899271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ; Hanauer SB
    Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.